Recipharm agrees to acquire Sanofi CMO business in UK

The acquisition of Sanofi’s manufacturing centre and business located in Holmes Chapel provides Recipharm with a solid platform to take further advantage of the growing respiratory drug market.

It also adds additional inhalation commercial drug product manufacturing capabilities, complementing services already offered by Recipharm’s inhalation development facility in the US.

The acquired business will enhance Recipharm’s scale and provide access to new customers and higher margin specialised technologies

Recipharm CEO Thomas Eldered said: “Holmes Chapel brings Recipharm an ideal opportunity to accelerate its offering to customers with access to novel of respiratory products. As an already successful CMO with several clients, we look forward to introducing new contracts to Holmes Chapel by utilising our growing franchise in development services.

“Treatments for asthma and chronic obstructive pulmonary disease (COPD) are growing at a fast rate and we see many opportunities. The experienced management team and staff have already successfully attracted new customers and we look forward to building on this from the well invested facility.”

The Holmes Chapel manufacturing facility is located close to Manchester and is one of the leading sites of its type in Europe providing CMO manufacturing services. Several clients are serviced from the facility and a number of products, some of which that are still in their launch phase, are supplied.

One such client is Vectura Group plc, for whom flutiform® is manufactured. As part of the transaction Sanofi have also entered into a long-term supply agreement for the products currently manufactured at the facility.

The prime technologies of Holmes Chapel are metered dose inhalers and nasal sprays. The facility houses development areas for dry powder inhalation technologies.

The site covers 125,000 m2 and is home to a team of more than 450 specialist employees.

Source: Company Press Release